PeterMD Tirzepatide Review: Cost, Quarterly Billing & Honest Verdict (2026)

PeterMD is a men's-health telehealth platform covering TRT, peptide therapy, sexual health, and anti-aging alongside compounded GLP-1s. Its entry price ($149 to start) is low and but tirzepatide is structured differently from most competitors: it's billed quarterly at $249/month, meaning each renewal is a single charge of roughly $747, not a monthly one. Every fact here comes from the company's own published program.

What PeterMD is

PeterMD is a men's-health telehealth platform, covering TRT, peptide therapy, sexual health, and anti-aging alongside compounded GLP-1s, with transparent published pricing and no insurance involved. Its compounded semaglutide is priced separately and, is among the cheapest anywhere at a flat $105/month billed monthly across every dose tier.

The quarterly billing structure — a real catch worth understanding

PeterMD's tirzepatide pricing works differently from most compounded providers: $149 gets you started, then $249/month billed quarterly against a struck-through $315 — meaning each renewal is a single charge of roughly $747, not a monthly one. Cancellation is month-to-month through the patient portal with no fee, but the quarterly billing cycle means canceling at the wrong moment is expensive — you can't simply stop after one month without eating most of a quarter's charge.

The brand-vs-compounded question

PeterMD dispenses compounded tirzepatide, often paired with B12 not the FDA-approved branded product. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

PeterMD's real strengths: transparent published pricing with no insurance required, month-to-month cancellation through the patient portal with no fee, and coverage of the men's-health adjacencies (TRT, peptides, ED, anti-aging) on one account. Its compounded semaglutide, is genuinely cheap at a flat $105/month across every dose tier. The trade-offs: tirzepatide's quarterly billing means each renewal is a roughly $747 lump charge rather than a predictable monthly one; PeterMD is not available in eight states (AL, AR, CA, HI, ID, MI, NC, TX); its branding is men's-only, which won't suit women seeking GLP-1 access; and its compounding pharmacy and prescribing clinicians are not publicly named. As with any GLP-1 program, understand the billing cycle before you sign up; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

PeterMD's $149 entry price is genuinely low, but the real ongoing cost is a roughly $747 quarterly charge, not a monthly $249 — read the billing structure carefully before you sign up. If a predictable monthly charge matters more, compare it against CoreAge Rx or MyStart Health's price-locked monthly rate. See our best tirzepatide providers ranking for the full field.